ACOS syndrome: Single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD?
Date
2016Language
en
Keyword
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) represent two major public health problems. However, there is a significant proportion of patients with a mixed asthma-COPD phenotype. This condition is defined as asthma-COPD overlap syndrome (ACOS). Since there are no internationally accepted criteria for the diagnosis of that syndrome, its management remains difficult. Given the fact that patients with ACOS have an increased risk of exacerbation and hospitalization, there is a pressing need for a more targeted approach and better management. We propose that fractional exhaled nitric oxide (FeNO), a marker of eosinophilic inflammation, could help clinicians differentiate ACOS from asthma and COPD. We evaluate this hypothesis, using data derived from the existing literature. © 2016 Elsevier Ltd.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Fractional exhaled nitric oxide: Signaling lung function changes in obstructive lung diseases
Kotsiou O.S., Gourgoulianis K.I. (2018)[No abstract available] -
Fractional exhaled nitric oxide: where there is smoke, there is fire
Kotsiou O.S., Gourgoulianis K.I., Daniil Z. (2021)[No abstract available] -
Enigma variations: The multi-faceted problems of pre-school wheeze
Chatziparasidis G., Bush A. (2022)Numerous publications on wheezing disorders in children younger than 6 years have appeared in the medical literature over the last decades with the aim of shedding light on the mechanistic pathways (endotypes) and treatment. ...